Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Transfusion Medicine and Hemotherapy

• Publication date

  2011-01-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1159/000324458PMID 21779204PMCID PMC3132978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions

  2012cited by this paper
• Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period

  2011cited by this paper
• The status of pathogen-reduced plasma.

  2010cited by this paper
• A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

  2010cited by this paper
• The curtain is still going up

  2010cited by this paper
• Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress

  2010cited by this paper
• Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

  2010cited by this paper
• Community blood donors' knowledge of anemia and design of a literacy‐appropriate educational intervention

  2010cited by this paper
• An association between decreased cardiopulmonary complications (transfusion‐related acute lung injury and transfusion‐associated circulatory overload) and implementation of universal leukoreduction of blood transfusions

  2010cited by this paper
• Influence of prestorage leukoreduction and subsequent irradiation on in vitro red blood cell (RBC) storage variables of RBCs in additive solution saline‐adenine‐glucose‐mannitol

  2009cited by this paper
• Does red blood cell storage affect clinical outcome? When in doubt, do the experiment

  2009cited by this paper
• Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug‐induced nonimmunologic protein adsorption

  2009cited by this paper
• Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model.

  2009cited by this paper
• Dengue virus in blood donations, Puerto Rico, 2005

  2008cited by this paper
• Neutrophil priming, caused by cell membranes and microvesicles in packed red blood cell units, is abrogated by leukocyte depletion at collection.

  2008cited by this paper
• Pathogen Reduction: A Precautionary Principle Paradigm

  2008cited by this paper
• Serological studies of piperacillin antibodies

  2008cited by this paper
• External quality assessment for the detection of HCV RNA, HIV RNA and HBV DNA in plasma by nucleic acid amplification technology: a novel approach

  2008cited by this paper
• The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two‐bottle culture systems and an estimation of false‐negative culture rates

  2007cited by this paper
• Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study

  2007cited by this paper
• Pathogen inactivation: making decisions about new technologies

  2007cited by this paper
• A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

  2006cited by this paper
• Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.

  2006cited by this paper
• Fatal transfusion‐associated graft‐versus‐host disease in an immunocompetent recipient of a volunteer unit of red cells

  2006cited by this paper
• Babesiosis and blood transfusion: flying under the radar

  2006cited by this paper
• Viability of red cells prepared with S‐303 pathogen inactivation treatment

  2006cited by this paper
• Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function

  2006cited by this paper
• Professor J. J. van Loghem

  2005cited by this paper
• Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set

  2005cited by this paper
• Therapeutic efficacy and safety of red blood cells treated with a chemical process (S‐303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients

  2005cited by this paper
• Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

  2004cited by this paper
• Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria

  2004cited by this paper
• A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies

  2004cited by this paper
• Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion.

  2004cited by this paper
• Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.

  2003cited by this paper
• Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.

  2003cited by this paper
• HLA and RBC immunization after filtered and buffy coat‐depleted blood transfusion in cardiac surgery: a randomized controlled trial

  2003cited by this paper
• Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?

  2001cited by this paper
• Principles of blood irradiation, dose validation, and quality control

  1997cited by this paper
• A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions

  1993cited by this paper

• A novel acridine flow cytometry marker to track post‐transfusion amustaline/glutathione pathogen‐reduced red blood cell survival in sickle cell disease patients

  2025influential citation
• Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial

  2025cites this paper
• Amustaline/glutathione pathogen‐reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial

  2025cites this paper
• Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

  2025cites this paper
• Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients

  2025cites this paper
• Effects of an amustaline (S‐303)/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood

  2025cites this paper
• It's in your blood: The impact of age, sex, genetic factors and exposures on stored red blood cell metabolism.

  2024cites this paper
• Characterizing the antibody response to amustaline/glutathione pathogen‐reduced red blood cells

  2024cites this paper
• Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial

  2023cites this paper
• Pathogen reduced red blood cells as an alternative to irradiated and washed components with potential for up to 42 days storage

  2023cites this paper
• CT- and MRI-Aided Fluorescence Tomography Reconstructions for Biodistribution Analysis

  2023cites this paper
• New ultraviolet C light‐based method for pathogen inactivation of red blood cell units

  2022cites this paper
• Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction

  2022cites this paper
• Is pathogen reduction an acceptable alternative to irradiation for risk mitigation of transfusion-associated graft versus host disease?

  2022cites this paper
• Inactivation of Plasmodium falciparum in whole blood using the amustaline and glutathione pathogen reduction technology

  2020cites this paper
• Prevalence of natural and acquired antibodies to amustaline/glutathione pathogen reduced red blood cells

  2020cites this paper
• New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

  2020cites this paper
• Changing Landscaping in Transfusion-Transmitted Infections

  2020cites this paper
• Progress towards an appropriate pathogen reduction technology for whole blood in Africa

  2020cites this paper
• The long and winding road to pathogen reduction of platelets, red blood cells and whole blood

  2019cites this paper
• Pathogen Reduction: The State of the Science in 2019.

  2019cites this paper
• Nucleic acid‐targeted pathogen reduction technique in red blood cells by UV‐generated oxygen radicals for optimising recipient safety

  2019cites this paper
• Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

  2019cites this paper
• Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors

  2019cites this paper
• Pathogen Reduction Technologies

  2019cites this paper
• Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

  2019cites this paper
• Red blood cells treated with the amustaline (S‐303) pathogen reduction system: a transfusion study in cardiac surgery

  2018influential citation
• Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione

  2018cites this paper
• Metody inaktywacji biologicznych czynników chorobotwórczych w koncentracie krwinek czerwonych i krwi pełnej

  2018cites this paper
• Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine

  2017cites this paper
• Red blood cell hemolysis : protein biomarker discovery for product quality assessment

  2017cites this paper
• Prevention of transfusion‐transmitted malaria

  2017cites this paper
• Blood Product Administration Safety

  2017cites this paper
• Evaluation of a new microbeads assay for granulocyte antibody detection

  2017cites this paper
• Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

  2017cites this paper
• Amustaline (S‐303) treatment inactivates high levels of Zika virus in red blood cell components

  2017cites this paper
• Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

  2017cites this paper
• Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion

  2017influential citation
• Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood

  2017cites this paper
• Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation

  2016cites this paper
• Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk.

  2016cites this paper
• Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: A systematic review with regional discussion

  2016cites this paper
• Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium

  2016cites this paper
• Targeting of blood safety measures to affected areas with ongoing local transmission of malaria

  2016cites this paper
• with Basic Side Chains

  2016cites this paper
• Classic and alternative red blood cell storage strategies: seven years of "-omics" investigations.

  2015cites this paper
• Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation

  2015influential citation
• Large animal evaluation of riboflavin and ultraviolet light–treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model

  2015cites this paper
• Phenothiazinium photoantimicrobials with basic side chains.

  2015cites this paper
• Pathogen reduction technologies

  2014cites this paper
• Red blood cell in vitro quality and function is maintained after S‐303 pathogen inactivation treatment

  2014influential citation
• Pathogen Inactivation Technologies for Cellular Blood Components: an Update

  2014cites this paper
• Chemical and Biological Mechanisms of Pathogen Reduction Technologies

  2014cites this paper
• Is self-sufficiency in haemotherapies a practical or necessary goal?

  2013cites this paper
• Component pathogen inactivation: a critical review

  2013cites this paper
• Update on pathogen reduction technology

  2013cites this paper
• Pathogen Reduction Technologies: The Best Solution for Safer Blood?

  2013cites this paper
• Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

  2013cites this paper
• Emerging Pathogens - How Safe is Blood?

  2013cites this paper
• Transfusion‐transmitted babesiosis: achieving successful mitigation while balancing cost and donor loss

  2012cites this paper
• Pathogen reduction in blood components: current technologies and future trends

  2012cites this paper
• Pathogen Reduction in Blood Products: What’s Behind These Techniques?

  2011cites this paper
• Proteomics of blood and derived products: what’s next?

  2011cites this paper
• Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria

  2011cites this paper
• Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety

  year unknowncites this paper